



Novartis Pharma B.V.
The Netherlands

Integrity in reimagining medicine


Tanya Sluyter, Country Head Ethics, Risk & Compliance
RadboudUMC Research Integrity Round
December 1st, 2021

We have a vital purpose, supported by a strong culture with clear values



Purpose

Reimagine medicine to improve and extend people's lives



Values

Inspired | Curious | Unbossed | Integrity

Novartis worldwide – figures 2020



110 738

associates supporting patients in 155 countries



160+ pipeline projects in clinical development



26 major regulatory approvals in the US, EU, Japan and China



769 million patients reached with our medicines, worldwide



66 million people treated through access activities



1 billion malaria treatments made available at cost price in the past two decades



7 cell and gene therapy studies now being tested in hospitals



\$ 9.0 billion invested in R&D (= 18.5% of our net sales)



\$ 48.7 billion net sales

What is the total amount of investments in R&D to hospitals/universities by all pharma companies in NL in 2020?

- 13,5 million Euro
- 90 million Euro
- 135 million Euro
- 900 million Euro

We aim to create value for our company, our shareholders and society

- Our strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science
- We have five strategic priorities



Unleash the power of our people



Deliver transformative innovation



Embrace operational excellence



Go big on data and digital



Build trust with society


Holding ourselves to high ethical standards



We create a culture of integrity and want to demonstrate ethical leadership

P3 introduces a simple set of questions to inform sound ethical decisions

P3 Principles



- Are we **putting the patient first**?
- Are we **engaging appropriately**?
- Are we **acting with clear intent**?
- Are we **funding responsibly**?
- Are we **researching for the right reason**?

Ethics, Risk & Compliance

We need to act ethically, manage risk and reliably achieve our company objectives

- **Ethics** – we empower associates to do what's right
- **Risks** – we establish effective risk management that identifies, analyzes, and addresses risks that can affect our operations
- **Compliance** – we ensure we act in compliance with applicable regulations, laws, policies and guidelines because doing what's right matter for patients, society and Novartis

Our Code of Ethics consists of two elements

1

Our **Ethical Principles** explaining what '*doing what's right*' means in the Novartis context and support associates to make good decisions on ethical challenges

2

Statements on our **Commitment** to doing what's right across key areas reflecting important topics to our business and are a reference for behaviors we expect to see

Would you consider working for an innovative pharmaceutical company?

- No, not at this moment
- I did not consider this until today, but I'm more open to it now
- Yes, but only as a scientist
- Yes, and not only as a scientist


Novartis Institutes for BioMedical Research (NIBR)

- The innovation engine of Novartis
- Discovering innovative new drugs changing the practice of medicine
- **6000** scientists dedicated to discovery
- **6** research campuses across the globe
- **+300** academic alliances
- **100** industry alliances




Novartis Institutes for BioMedical Research / NIBR

Worldwide network – innovative research



From the lab to the patient



Total costs: \$ 2-4 miljard

Significant R&D investments in 2020 – 119 Novartis trials supported and >1791 patients in clinical trials

Clinical Trials	
Phase I	20
Phase II	36
Phase III	53
Phase IV	8
IIT	29





Thank you